Adult Stem Cell Treatment of Scleroderma

Alan Tyndall; Daniel E. Furst


Curr Opin Rheumatol. 2007;19(6):604-610. 

In This Article


In conclusion, HSCT for SSc has advanced to the stage of two international prospective randomized controlled trials which should determine if this aggressive form of therapy may 'reset' an autoaggressive immune system and benefit patients with severe, poor prognosis SSC. During the past several years the potential use of MSCs as immunomodulating agents is being explored (e.g. in the acute GvHD setting in which a positive effect seems possible with little or no acute toxicity). Preliminary results suggest that bone marrow-derived MSCs from SSc patients exhibit effective in-vitro antiproliferative effects on lymphocytes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.